当前位置： SCI文献检索 > Journal of Cancer Research and Therapeutics期刊下所有文献 > Definitive chemoradiotherapy in Stage III nonsmall cell lung cancer: Turkey experience.

Definitive chemoradiotherapy in Stage III nonsmall cell lung cancer: Turkey experience.

Abstract：

AIM:Concurrent chemoradiotherapy (CRT) is the standard therapy for patients with unresectable Stage III nonsmall cell lung cancer (NSCLC). The aim of this study was to assess the efficacy and safety of concurrent CRT in unresectable Stage III NSCLC in Turkey. PATIENTS AND METHODS:The study included 82 patients with histologically proven unresectable Stage III NSCLC, Eastern Cooperative Oncology Group performance status 0-1, who received concurrent CRT in two different referral centers. Treatment consisted of two cycles of cisplatin at 50 mg/m 2 on days 1, 8, 29, and 36 and etoposide 50 mg/m 2 between days 1 and 5, 29-33 and concurrent radiotherapy administered once daily, 1.8-2.0 Gy per fraction, at a total dose of 60-66 Gy. RESULTS:The stages of the patients were Stage IIIA in 39 (47.5%) and IIIB in 43 (52.5%) patients. Complete and partial responses were achieved in 15 (18.2%) and 31 (37.8%) of the patients, respectively. Twenty-eight (34.2%) patients had stable disease and 8 (9.8) had progressive disease. Forty-one (50%) patients recurred during follow-up. The primary site of recurrence was as distant metastasis in 19 (23.2%) patients. Median overall survival (OS) was 20 months (95% confidence interval; 12.9-27.09 months), 3 and 4 years survivals were 27.9% and 20.9%, respectively. Median progression-free survival (PFS) was 9 months, 3 and 4 years PFSs were 20.1% and 16.1%. Myelosuppression was the most common toxicity. In 15 (19.2%) patients grade 2-3 lung toxicity and in seven (8.5%) patients' grade 2-3 dysphagia were reported. CONCLUSION:Concurrent CRT with cisplatin and etoposide schedule is a well-tolerated regimen with acceptable toxicity profile and survival rates in patients with unresectable Stage IIIA/IIIB NSCLC. Median survival and OS results were consistent with the literature.

journal_name

J Cancer Res Ther

journal_title

Journal of cancer research and therapeutics

authors

Yilmaz U,Yılmaz U,Yasar Z,Kıraklı EK,Ulger S,Ozdogan Y,Demirci NY,Erol S,Ozdogan I,Sahin B,Koksal D,Akcay C

doi

10.4103/0973-1482.163682

subject

Has Abstract

pub_date

2016-01-01 00:00:00

pages

334-9

issue

eissn

0973-1482

issn

1998-4138

pii

JCanResTher_2016_12_1_334_163682

journal_volume

pub_type

杂志文章

在线工具

Definitive chemoradiotherapy in Stage III nonsmall cell lung cancer: Turkey experience.